Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma

Purpose 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deau...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine and molecular imaging Vol. 53; no. 4; pp. 263 - 269
Main Authors Boo, Sun Ha, O, Joo Hyun, Kwon, Soo Jin, Yoo, Ie Ryung, Kim, Sung Hoon, Park, Gyeong Sin, Choi, Byung Ock, Jung, Seung Eun, Cho, Seok-Goo
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2019
Springer Nature B.V
대한핵의학회
Subjects
Cardiology
Chemotherapy
Computed tomography
Confidence intervals
Fluorine isotopes
Imaging
Lymphoma
Medicine
Medicine & Public Health
Multivariate analysis
Nuclear Medicine
Oncology
Original
Original Article
Orthopedics
Positron emission
Radiology
Rank tests
Regression analysis
Statistical analysis
Survival
Survival analysis
Tomography
방사선과학
Follicular lymphoma
Lugano classification
Positron emission tomography
Progression-free survival
F-fluorodeoxyglucose
18F-fluorodeoxyglucose
Online AccessGet full text
ISSN1869-3474
1869-3482
DOI10.1007/s13139-019-00602-0

Cover

Abstract Purpose 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PET Interim ) and end-of-induction therapy PET/CT (PET EOI ) in patients with FL. Methods FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PET Interim was performed 3 or 4 cycles after chemotherapy and PET EOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan–Meier survival analysis, and the log-rank test. Results Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PET Interim , 23 patients were negative and 10 were positive. On PET EOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PET EOI (−) was associated with longer PFS. PET Interim (+) and PET EOI (+) patients had a significantly shorter PFS than PET Interim (−) patients (39.9 months, 95% confidence interval [CI] 23.0–56.9, versus 55.5 months, 95% CI 49.7–61.2, p  = 0.005) and PET EOI (−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p  < 0.001). Conclusion For patients with FL, PET Interim and PET EOI response is predictive of PFS, and PET EOI (+) is an independent prognostic factor for progression of FL.
AbstractList 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PETInterim) and end-of-induction therapy PET/CT (PETEOI) in patients with FL.PURPOSE18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PETInterim) and end-of-induction therapy PET/CT (PETEOI) in patients with FL.FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PETInterim was performed 3 or 4 cycles after chemotherapy and PETEOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (-), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan-Meier survival analysis, and the log-rank test.METHODSFL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PETInterim was performed 3 or 4 cycles after chemotherapy and PETEOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (-), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan-Meier survival analysis, and the log-rank test.Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5-72.7 months). On PETInterim, 23 patients were negative and 10 were positive. On PETEOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PETEOI(-) was associated with longer PFS. PETInterim(+) and PETEOI(+) patients had a significantly shorter PFS than PETInterim(-) patients (39.9 months, 95% confidence interval [CI] 23.0-56.9, versus 55.5 months, 95% CI 49.7-61.2, p = 0.005) and PETEOI(-) patients (14.2 months, 95% CI 8.5-19.8, versus 60.5 months, 95% CI 52.1-69.0, p < 0.001).RESULTSThirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5-72.7 months). On PETInterim, 23 patients were negative and 10 were positive. On PETEOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PETEOI(-) was associated with longer PFS. PETInterim(+) and PETEOI(+) patients had a significantly shorter PFS than PETInterim(-) patients (39.9 months, 95% confidence interval [CI] 23.0-56.9, versus 55.5 months, 95% CI 49.7-61.2, p = 0.005) and PETEOI(-) patients (14.2 months, 95% CI 8.5-19.8, versus 60.5 months, 95% CI 52.1-69.0, p < 0.001).For patients with FL, PETInterim and PETEOI response is predictive of PFS, and PETEOI(+) is an independent prognostic factor for progression of FL.CONCLUSIONFor patients with FL, PETInterim and PETEOI response is predictive of PFS, and PETEOI(+) is an independent prognostic factor for progression of FL.
Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PETInterim) and end-of-induction therapy PET/CT (PETEOI) in patients with FL. Methods FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PETInterim was performed 3 or 4 cycles after chemotherapy and PETEOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan–Meier survival analysis, and the log-rank test. Results Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CTstudies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PETInterim, 23 patients were negative and 10 were positive. On PETEOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PETEOI(−) was associated with longer PFS. PETInterim(+) and PETEOI(+) patients had a significantly shorter PFS than PETInterim(−) patients (39.9 months, 95%confidence interval [CI] 23.0–56.9, versus 55.5months, 95%CI 49.7–61.2, p =0.005) and PETEOI(−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p< 0.001). Conclusion For patients with FL, PETInterim and PETEOI response is predictive of PFS, and PETEOI(+) is an independent prognostic factor for progression of FL. KCI Citation Count: 0
Purpose 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PET Interim ) and end-of-induction therapy PET/CT (PET EOI ) in patients with FL. Methods FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PET Interim was performed 3 or 4 cycles after chemotherapy and PET EOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan–Meier survival analysis, and the log-rank test. Results Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PET Interim , 23 patients were negative and 10 were positive. On PET EOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PET EOI (−) was associated with longer PFS. PET Interim (+) and PET EOI (+) patients had a significantly shorter PFS than PET Interim (−) patients (39.9 months, 95% confidence interval [CI] 23.0–56.9, versus 55.5 months, 95% CI 49.7–61.2, p  = 0.005) and PET EOI (−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p  < 0.001). Conclusion For patients with FL, PET Interim and PET EOI response is predictive of PFS, and PET EOI (+) is an independent prognostic factor for progression of FL.
F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PET ) and end-of-induction therapy PET/CT (PET ) in patients with FL. FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PET was performed 3 or 4 cycles after chemotherapy and PET after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (-), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan-Meier survival analysis, and the log-rank test. Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5-72.7 months). On PET , 23 patients were negative and 10 were positive. On PET scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PET (-) was associated with longer PFS. PET (+) and PET (+) patients had a significantly shorter PFS than PET (-) patients (39.9 months, 95% confidence interval [CI] 23.0-56.9, versus 55.5 months, 95% CI 49.7-61.2,  = 0.005) and PET (-) patients (14.2 months, 95% CI 8.5-19.8, versus 60.5 months, 95% CI 52.1-69.0,  < 0.001). For patients with FL, PET and PET response is predictive of PFS, and PET (+) is an independent prognostic factor for progression of FL.
Purpose18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PETInterim) and end-of-induction therapy PET/CT (PETEOI) in patients with FL.MethodsFL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PETInterim was performed 3 or 4 cycles after chemotherapy and PETEOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan–Meier survival analysis, and the log-rank test.ResultsThirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PETInterim, 23 patients were negative and 10 were positive. On PETEOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PETEOI(−) was associated with longer PFS. PETInterim(+) and PETEOI(+) patients had a significantly shorter PFS than PETInterim(−) patients (39.9 months, 95% confidence interval [CI] 23.0–56.9, versus 55.5 months, 95% CI 49.7–61.2, p = 0.005) and PETEOI(−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p < 0.001).ConclusionFor patients with FL, PETInterim and PETEOI response is predictive of PFS, and PETEOI(+) is an independent prognostic factor for progression of FL.
Author Cho, Seok-Goo
Kwon, Soo Jin
Choi, Byung Ock
Boo, Sun Ha
O, Joo Hyun
Park, Gyeong Sin
Yoo, Ie Ryung
Jung, Seung Eun
Kim, Sung Hoon
Author_xml – sequence: 1
  givenname: Sun Ha
  surname: Boo
  fullname: Boo, Sun Ha
  organization: Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 2
  givenname: Joo Hyun
  orcidid: 0000-0002-6568-5915
  surname: O
  fullname: O, Joo Hyun
  email: ojoohyun@catholic.ac.kr
  organization: Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 3
  givenname: Soo Jin
  surname: Kwon
  fullname: Kwon, Soo Jin
  organization: Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 4
  givenname: Ie Ryung
  surname: Yoo
  fullname: Yoo, Ie Ryung
  organization: Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 5
  givenname: Sung Hoon
  surname: Kim
  fullname: Kim, Sung Hoon
  organization: Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 6
  givenname: Gyeong Sin
  surname: Park
  fullname: Park, Gyeong Sin
  organization: Department of Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 7
  givenname: Byung Ock
  surname: Choi
  fullname: Choi, Byung Ock
  organization: Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 8
  givenname: Seung Eun
  surname: Jung
  fullname: Jung, Seung Eun
  organization: Department of Radiology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 9
  givenname: Seok-Goo
  surname: Cho
  fullname: Cho, Seok-Goo
  organization: Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31456859$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002492270$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9Ul1v2yAURVOntev6B_YwIe1le_DKh43xy6QqS7pIkRZNbl8RAdzQ2pCC3Sn_fiTu0q4PRUIXiXMO53LPe3DkvDMAfMToG0aoPI-YYlplCKeNGCIZegNOMGdVRnNOjg7nMj8GZzHeorQoqRAt34FjivOC8aI6AatlMNqq3j4YeC3bwUDfwLnrTbAdlE7DqdOZb7J6bYLcbCHms2z24xIup_X5pIbWwaXsrXF9hH9sv4Yz37ZWDa0McLHtNmvfyQ_gbSPbaM4e6ym4mk3ryc9s8etyPrlYZKpAvM-0ZDzHsmRUc8a0LlhDm7T0SmFJkSKGsRxVDUG4WDFdNGWpqVQK5xRXlEh6Cr6Oui404k5Z4aXd1xsv7oK4-F3PRVExXFCUsN9H7GZYdUar1ECQrdikrmXY7pn_3zi7TjoPgrEqpzlJAl8eBYK_H0zsRWejMm0rnfFDFIRwzHNWIpygn19Ab_0QXPqKhCopJbxgO0efnjs6WPk3qgQgI0AFH2MwzQGCkdhFQoyRECkSYh8JsVPlL0jK9mlgfteVbV-n0pEa0zvuxoQn26-w_gLg48gT
CitedBy_id crossref_primary_10_2214_AJR_19_22642
crossref_primary_10_1016_j_remn_2022_03_001
crossref_primary_10_1007_s00277_023_05138_0
crossref_primary_10_7759_cureus_75169
crossref_primary_10_1186_s12885_025_13507_3
crossref_primary_10_1016_j_remnie_2022_03_002
crossref_primary_10_1007_s10278_023_00823_y
crossref_primary_10_1007_s13139_022_00782_2
crossref_primary_10_1007_s10967_024_09359_z
crossref_primary_10_1038_s41598_021_98081_x
crossref_primary_10_3390_biomedicines9050561
crossref_primary_10_1186_s12935_021_02094_5
crossref_primary_10_1097_HS9_0000000000000826
crossref_primary_10_3390_cancers17071065
Cites_doi 10.1007/s00259-012-2079-y
10.3816/CLM.2008.n.040
10.1016/j.ijrobp.2007.09.051
10.1182/blood-2011-06-359943
10.1093/annonc/mdt137
10.1007/s12149-014-0874-1
10.1007/s13139-015-0368-7
10.3816/CLM.2007.n.005
10.3322/caac.21357
10.1200/JCO.2013.54.8800
10.1093/annonc/mdt562
10.1093/annonc/mdq574
10.1111/j.1365-2141.2011.08969.x
10.1200/JCO.2012.43.0934
10.1182/blood-2011-01-293050
10.1093/annonc/mdu200
10.1200/JCO.2016.66.9440
10.1007/s13139-018-0543-8
10.1056/NEJMoa1510093
10.1016/S2352-3026(14)70008-0
10.1080/10428190903040048
10.1016/S0140-6736(10)62175-7
10.1200/JCO.2006.08.2305
10.1007/s00259-013-2435-6
10.1038/bjc.2015.94
10.1080/10428190701422059
10.1111/j.1365-2141.2011.08942.x
10.2967/jnumed.112.110890
10.1007/s00259-010-1539-5
10.1200/JCO.2011.35.0736
ContentType Journal Article
Copyright Korean Society of Nuclear Medicine 2019
Copyright Springer Nature B.V. 2019
Copyright_xml – notice: Korean Society of Nuclear Medicine 2019
– notice: Copyright Springer Nature B.V. 2019
DBID AAYXX
CITATION
NPM
NAPCQ
7X8
5PM
ACYCR
DOI 10.1007/s13139-019-00602-0
DatabaseName CrossRef
PubMed
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


PubMed
Nursing & Allied Health Premium
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1869-3482
EndPage 269
ExternalDocumentID oai_kci_go_kr_ARTI_5961530
PMC6694342
31456859
10_1007_s13139_019_00602_0
Genre Journal Article
GroupedDBID ---
-EM
.UV
06D
0R~
0VY
1N0
203
29~
2KG
30V
4.4
406
408
40D
67Z
8JR
96X
9ZL
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
AAZMS
ABAKF
ABDZT
ABECU
ABFTV
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACKNC
ACMDZ
ACMLO
ACOKC
ACPIV
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
AOCGG
AOIJS
ASPBG
AVWKF
AXYYD
AZFZN
BAWUL
BGNMA
CSCUP
DDRTE
DIK
DNIVK
DPUIP
EBLON
EBS
EF.
EIOEI
EJD
ESBYG
F5P
FERAY
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ6
GQ7
HMJXF
HRMNR
HYE
I0C
IKXTQ
IWAJR
IXD
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O9J
OK1
P9S
PT4
R9I
RLLFE
ROL
RPM
RSV
S27
S37
S3B
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
T13
TSG
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
Z45
ZMTXR
ZOVNA
~A9
2VQ
AAAVM
AANXM
AAPKM
AARHV
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEBTG
AEZWR
AFDZB
AFHIU
AFLOW
AFOHR
AHPBZ
AHSBF
AHWEU
AIXLP
AJBLW
ATHPR
AYFIA
CITATION
FEDTE
H13
HF~
HVGLF
HZ~
O9-
ABRTQ
NPM
NAPCQ
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c508t-da6841a763d866dd56f3ffffdbc1a30c2e66409f2015b6d5f77d3acc1431932a3
IEDL.DBID U2A
ISSN 1869-3474
IngestDate Sun Mar 09 07:52:42 EDT 2025
Thu Aug 21 14:10:41 EDT 2025
Fri Jul 11 09:18:05 EDT 2025
Wed Sep 03 00:22:57 EDT 2025
Mon Jul 21 06:06:38 EDT 2025
Tue Jul 01 01:05:51 EDT 2025
Thu Apr 24 23:08:45 EDT 2025
Fri Feb 21 02:35:28 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Follicular lymphoma
Lugano classification
Positron emission tomography
Progression-free survival
F-fluorodeoxyglucose
18F-fluorodeoxyglucose
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-da6841a763d866dd56f3ffffdbc1a30c2e66409f2015b6d5f77d3acc1431932a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6568-5915
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6694342
PMID 31456859
PQID 2273328560
PQPubID 2044329
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_5961530
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6694342
proquest_miscellaneous_2281846701
proquest_journals_2273328560
pubmed_primary_31456859
crossref_primary_10_1007_s13139_019_00602_0
crossref_citationtrail_10_1007_s13139_019_00602_0
springer_journals_10_1007_s13139_019_00602_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-08-01
PublicationDateYYYYMMDD 2019-08-01
PublicationDate_xml – month: 08
  year: 2019
  text: 2019-08-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Nuclear medicine and molecular imaging
PublicationTitleAbbrev Nucl Med Mol Imaging
PublicationTitleAlternate Nucl Med Mol Imaging
PublicationYear 2019
Publisher Springer Berlin Heidelberg
Springer Nature B.V
대한핵의학회
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
– name: 대한핵의학회
References Luminari, Biasoli, Versari, Rattotti, Bottelli, Rusconi (CR15) 2014; 25
Metser, Mohan, Beckley, Moshonov, Hodgson, Murphy (CR26) 2016; 50
Janikova, Bolcak, Pavlik, Mayer, Kral (CR7) 2008; 8
Dupuis, Berriolo-Riedinger, Julian, Brice, Tychyj-Pinel, Tilly (CR12) 2012; 30
Luminari, Biasoli, Arcaini, Versari, Rusconi, Merli (CR9) 2013; 24
Trotman, Luminari, Boussetta, Versari, Dupuis, Tychyj (CR18) 2014; 1
Shustik, Quinn, Connors, Gascoyne, Skinnider, Sehn (CR22) 2010; 22
Biggi, Gallamini, Chauvie, Hutchings, Kostakoglu, Gregianin (CR29) 2013; 54
Lu, Lin, Downe, Chong, Ling (CR14) 2014; 28
Kim, Lee, Choi, Paeng, Cheon, Lee (CR27) 2018; 52
Le Dortz, De Guibert, Bayat, Devillers, Houot, Rolland (CR8) 2010; 37
Salles, Seymour, Offner, Lopez-Guillermo, Belada, Xerri (CR19) 2011; 377
Meignan, Gallamini, Meignan, Gallamini, Haioun (CR6) 2009; 50
Bishu, Quigley, Bishu, Olsasky, Stem, Shostrom (CR11) 2007; 48
Smith, Crouch, Lax, Li, Painter, Howell (CR1) 2015; 112
Lopci, Zanoni, Chiti, Fonti, Santi, Zinzani (CR13) 2012; 39
McNamara, Davies, Dyer, Hoskin, Illidge, Lyttelton (CR4) 2012; 156
Dreyling, Ghielmini, Marcus, Salles, Vitolo, Ladetto (CR20) 2014; 25
Cheson, Fisher, Barrington, Cavalli, Schwartz, Zucca (CR5) 2014; 32
Trotman, Fournier, Lamy, Seymour, Sonet, Janikova (CR16) 2011; 29
Itti, Meignan, Berriolo-Riedinger, Biggi, Cashen, Vera (CR28) 2013; 40
Juweid, Stroobants, Hoekstra, Mottaghy, Dietlein, Guermazi (CR25) 2007; 25
Wirth, Foo, Seymour, Macmanus, Hicks (CR10) 2008; 71
Goldman, Schafer (CR3) 2016
Pregno, Chiappella, Bello, Botto, Ferrero, Franceschetti (CR30) 2012; 119
Meignan, Cottereau, Versari, Chartier, Dupuis, Boussetta (CR24) 2016; 34
Teras, DeSantis, Cerhan, Morton, Jemal, Flowers (CR2) 2016; 66
Zinzani, Musuraca, Alinari, Fanti, Tani, Stefoni (CR17) 2007; 7
Campo, Swerdlow, Harris, Pileri, Stein, Jaffe (CR21) 2011; 117
Johnson, Federico, Kirkwood, Fosså, Berkahn, Carella (CR31) 2016; 374
Wahlin, Yri, Kimby, Holte, Delabie, Smeland (CR23) 2012; 156
M Dreyling (602_CR20) 2014; 25
P Pregno (602_CR30) 2012; 119
J Dupuis (602_CR12) 2012; 30
G Salles (602_CR19) 2011; 377
E Lopci (602_CR13) 2012; 39
PL Zinzani (602_CR17) 2007; 7
J Shustik (602_CR22) 2010; 22
M Meignan (602_CR24) 2016; 34
M Meignan (602_CR6) 2009; 50
S Luminari (602_CR9) 2013; 24
U Metser (602_CR26) 2016; 50
HJ Kim (602_CR27) 2018; 52
BE Wahlin (602_CR23) 2012; 156
J Trotman (602_CR18) 2014; 1
E Campo (602_CR21) 2011; 117
C McNamara (602_CR4) 2012; 156
ME Juweid (602_CR25) 2007; 25
BD Cheson (602_CR5) 2014; 32
A Smith (602_CR1) 2015; 112
A Janikova (602_CR7) 2008; 8
S Luminari (602_CR15) 2014; 25
P Johnson (602_CR31) 2016; 374
L Le Dortz (602_CR8) 2010; 37
E Itti (602_CR28) 2013; 40
LR Teras (602_CR2) 2016; 66
J Trotman (602_CR16) 2011; 29
Z Lu (602_CR14) 2014; 28
S Bishu (602_CR11) 2007; 48
L Goldman (602_CR3) 2016
A Wirth (602_CR10) 2008; 71
A Biggi (602_CR29) 2013; 54
References_xml – volume: 39
  start-page: 864
  year: 2012
  end-page: 871
  ident: CR13
  article-title: FDG PET/CT predictive role in follicular lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2079-y
– volume: 8
  start-page: 287
  year: 2008
  end-page: 293
  ident: CR7
  article-title: Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
  publication-title: Clin Lymphoma Myeloma
  doi: 10.3816/CLM.2008.n.040
– volume: 71
  start-page: 213
  year: 2008
  end-page: 219
  ident: CR10
  article-title: Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.09.051
– volume: 119
  start-page: 2066
  year: 2012
  end-page: 2073
  ident: CR30
  article-title: Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
  publication-title: Blood
  doi: 10.1182/blood-2011-06-359943
– volume: 24
  start-page: 2108
  year: 2013
  end-page: 2112
  ident: CR9
  article-title: The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt137
– volume: 28
  start-page: 805
  year: 2014
  end-page: 811
  ident: CR14
  article-title: The prognostic value of mid- and post-treatment [(18)F] fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma
  publication-title: Ann Nucl Med
  doi: 10.1007/s12149-014-0874-1
– volume: 50
  start-page: 46
  year: 2016
  end-page: 53
  ident: CR26
  article-title: FDG PET/CT response assessment criteria for patients with Hodgkin’s and non-Hodgkin’s lymphoma at end of therapy: a multiparametric approach
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-015-0368-7
– volume: 7
  start-page: 291
  year: 2007
  end-page: 295
  ident: CR17
  article-title: Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
  publication-title: Clin Lymphoma Myeloma
  doi: 10.3816/CLM.2007.n.005
– volume: 66
  start-page: 443
  year: 2016
  end-page: 459
  ident: CR2
  article-title: 2016 US lymphoid malignancy statistics by World Health Organization subtypes
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21357
– volume: 32
  start-page: 3059
  year: 2014
  end-page: 3068
  ident: CR5
  article-title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.8800
– volume: 25
  start-page: 442
  year: 2014
  end-page: 447
  ident: CR15
  article-title: The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt562
– volume: 22
  start-page: 1164
  year: 2010
  end-page: 1169
  ident: CR22
  article-title: Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq574
– volume: 156
  start-page: 446
  year: 2012
  end-page: 467
  ident: CR4
  article-title: Guidelines on the investigation and management of follicular lymphoma
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08969.x
– volume: 30
  start-page: 4317
  year: 2012
  end-page: 4322
  ident: CR12
  article-title: Impact of [(18)F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.43.0934
– year: 2016
  ident: CR3
  publication-title: Goldman-Cecil medicine. 25th edition. Ed
– volume: 117
  start-page: 5019
  year: 2011
  end-page: 5032
  ident: CR21
  article-title: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
  publication-title: Blood.
  doi: 10.1182/blood-2011-01-293050
– volume: 25
  start-page: iii76
  issue: Suppl 3
  year: 2014
  end-page: iii82
  ident: CR20
  article-title: Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu200
– volume: 34
  start-page: 3618
  year: 2016
  end-page: 3626
  ident: CR24
  article-title: Baseline metabolic tumor volume predicts outcome in high–tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.66.9440
– volume: 52
  start-page: 342
  year: 2018
  end-page: 349
  ident: CR27
  article-title: Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-018-0543-8
– volume: 374
  start-page: 2419
  year: 2016
  end-page: 2429
  ident: CR31
  article-title: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1510093
– volume: 1
  start-page: e17
  year: 2014
  end-page: e27
  ident: CR18
  article-title: Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(14)70008-0
– volume: 50
  start-page: 1257
  year: 2009
  end-page: 1260
  ident: CR6
  article-title: Report on the first international workshop on interim-PET scan in lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190903040048
– volume: 377
  start-page: 42
  year: 2011
  end-page: 51
  ident: CR19
  article-title: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(10)62175-7
– volume: 25
  start-page: 571
  year: 2007
  end-page: 578
  ident: CR25
  article-title: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.2305
– volume: 40
  start-page: 1312
  year: 2013
  end-page: 1320
  ident: CR28
  article-title: An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-013-2435-6
– volume: 112
  start-page: 1575
  year: 2015
  ident: CR1
  article-title: Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s haematological malignancy research network
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2015.94
– volume: 48
  start-page: 1548
  year: 2007
  end-page: 1555
  ident: CR11
  article-title: Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190701422059
– volume: 156
  start-page: 225
  year: 2012
  end-page: 233
  ident: CR23
  article-title: Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08942.x
– volume: 54
  start-page: 683
  year: 2013
  end-page: 690
  ident: CR29
  article-title: International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.110890
– volume: 37
  start-page: 2307
  year: 2010
  end-page: 2314
  ident: CR8
  article-title: Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1539-5
– volume: 29
  start-page: 3194
  year: 2011
  end-page: 3200
  ident: CR16
  article-title: Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.0736
– volume: 71
  start-page: 213
  year: 2008
  ident: 602_CR10
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.09.051
– volume: 52
  start-page: 342
  year: 2018
  ident: 602_CR27
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-018-0543-8
– volume: 50
  start-page: 1257
  year: 2009
  ident: 602_CR6
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190903040048
– volume: 377
  start-page: 42
  year: 2011
  ident: 602_CR19
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(10)62175-7
– volume: 40
  start-page: 1312
  year: 2013
  ident: 602_CR28
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-013-2435-6
– volume: 25
  start-page: 571
  year: 2007
  ident: 602_CR25
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.2305
– volume: 28
  start-page: 805
  year: 2014
  ident: 602_CR14
  publication-title: Ann Nucl Med
  doi: 10.1007/s12149-014-0874-1
– volume: 39
  start-page: 864
  year: 2012
  ident: 602_CR13
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2079-y
– volume: 7
  start-page: 291
  year: 2007
  ident: 602_CR17
  publication-title: Clin Lymphoma Myeloma
  doi: 10.3816/CLM.2007.n.005
– volume: 374
  start-page: 2419
  year: 2016
  ident: 602_CR31
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1510093
– volume: 24
  start-page: 2108
  year: 2013
  ident: 602_CR9
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt137
– volume: 1
  start-page: e17
  year: 2014
  ident: 602_CR18
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(14)70008-0
– volume: 22
  start-page: 1164
  year: 2010
  ident: 602_CR22
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq574
– volume-title: Goldman-Cecil medicine. 25th edition. Ed
  year: 2016
  ident: 602_CR3
– volume: 25
  start-page: iii76
  issue: Suppl 3
  year: 2014
  ident: 602_CR20
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu200
– volume: 117
  start-page: 5019
  year: 2011
  ident: 602_CR21
  publication-title: Blood.
  doi: 10.1182/blood-2011-01-293050
– volume: 30
  start-page: 4317
  year: 2012
  ident: 602_CR12
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.43.0934
– volume: 48
  start-page: 1548
  year: 2007
  ident: 602_CR11
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190701422059
– volume: 156
  start-page: 225
  year: 2012
  ident: 602_CR23
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08942.x
– volume: 156
  start-page: 446
  year: 2012
  ident: 602_CR4
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08969.x
– volume: 34
  start-page: 3618
  year: 2016
  ident: 602_CR24
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.66.9440
– volume: 112
  start-page: 1575
  year: 2015
  ident: 602_CR1
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2015.94
– volume: 66
  start-page: 443
  year: 2016
  ident: 602_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21357
– volume: 29
  start-page: 3194
  year: 2011
  ident: 602_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.0736
– volume: 32
  start-page: 3059
  year: 2014
  ident: 602_CR5
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.8800
– volume: 54
  start-page: 683
  year: 2013
  ident: 602_CR29
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.110890
– volume: 37
  start-page: 2307
  year: 2010
  ident: 602_CR8
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1539-5
– volume: 50
  start-page: 46
  year: 2016
  ident: 602_CR26
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-015-0368-7
– volume: 8
  start-page: 287
  year: 2008
  ident: 602_CR7
  publication-title: Clin Lymphoma Myeloma
  doi: 10.3816/CLM.2008.n.040
– volume: 119
  start-page: 2066
  year: 2012
  ident: 602_CR30
  publication-title: Blood
  doi: 10.1182/blood-2011-06-359943
– volume: 25
  start-page: 442
  year: 2014
  ident: 602_CR15
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt562
SSID ssj0000329037
Score 2.2152276
Snippet Purpose 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in...
F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid...
Purpose18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in...
18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid...
Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 263
SubjectTerms Cardiology
Chemotherapy
Computed tomography
Confidence intervals
Fluorine isotopes
Imaging
Lymphoma
Medicine
Medicine & Public Health
Multivariate analysis
Nuclear Medicine
Oncology
Original
Original Article
Orthopedics
Positron emission
Radiology
Rank tests
Regression analysis
Statistical analysis
Survival
Survival analysis
Tomography
방사선과학
Title Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma
URI https://link.springer.com/article/10.1007/s13139-019-00602-0
https://www.ncbi.nlm.nih.gov/pubmed/31456859
https://www.proquest.com/docview/2273328560
https://www.proquest.com/docview/2281846701
https://pubmed.ncbi.nlm.nih.gov/PMC6694342
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002492270
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Nuclear Medicine and Molecular Imaging , 2019, 53(4), , pp.263-269
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RVkJcEG9SSmUQN7BI4thJjtuyaXm02sMuKifLiWNYtU2qfRz498zktVooSKwUZaXMWt58Hs9ne_wZ4E0UY5hITcJlHigeRc7y3KUWPR6juw19KxVtcD47V6ez6NOFvOg2hS37bPd-SbLpqTeb3QSyFRz64uUrypvdgT2JY3dyx1k4GmZWfBGmfiOWScctcRHFUbdb5vZitiLSTrVwt5HNP3Mmf1s4beJR9gDud0SSjVrkH8KdsnoEd8-6pfLHkE8W9J16M_bVXK1LVjvWzP_Nr5mpLBtXlteOT1tZARYkGc8-nLDJePr-eMrmFZu0kqtLRnO1LCP17iZplX35iU2gvjZPYJaNp8envDtQgRfIw1bcGpVEgcEuxSZKWcJBOPzYvAiM8IuwVAqRc0gKZK6sdHFshSkK5FTE84x4CrtVXZXPgaVYljQqTknwLpKxSYXMU1U4m0iJBXoQ9C9VF53aOB16caU3OskEhEYgdAOE9j14O_zmptXa-Kf1a8RKXxZzTRLZdP9e68uFxoHARy1TYrJodNBDqTvnXOoQKZsIE-R6HrwaHqNb0VqJqcp6TTbIZDCI-IEHz1rkhzqJAFlnIlMP4q02MRhQfbafVPMfjXS3UqTHF3rwrm89m2r9_a_u_5_5C7gXNu2b0hQPYHe1WJcvkTqt8kPYG2VHR-d0P_n2eXzYeM4v7hMOeA
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RIgEXxJvQFgziBhZJHDvJsSobtrBb7SGLerOcOIFV2wTt48C_70xeq6UFiUhRImViOflsz2d7_BngfRCim4hNxGXmKR4EpeVZGVus8ejdre9aqWiB8_RMjefB13N53i0KW_XR7v2UZNNSbxe7CWQr2PXF01UUN7sHd5EMRLRvwdw_HkZWXOHHbiOWSdstcRGEQbda5vZkdjzSXrUsbyObN2Mm_5g4bfxR8ggedkSSHbfIP4Y7RfUE7k27qfKnkM2WdE-tGftuLjcFq0vWjP8trpipLBtVltclT1tZAeZFCU8-f2GzUfrpJGWLis1aydUVo7FalpB6dxO0yia_sQjUV-YZzJNRejLm3YYKPEcetubWqCjwDDYpNlLKEg6ixMNmuWeEm_uFUohciaRAZsrKMgytMHmOnIp4nhHPYb-qq-IlsBjTkkaFMQneBTI0sZBZrPLSRlJigg54_U_Veac2TpteXOqtTjIBoREI3QChXQc-DO_8arU2_mn9DrHSF_lCk0Q2XX_U-mKpsSNwqmVMTBaNDnsodVc5V9pHyib8CLmeA2-Hx1itaK7EVEW9IRtkMuhEXM-BFy3yQ56Eh6wzkrED4U6ZGAwoP7tPqsXPRrpbKdLj8x342Jeebbb-_qmv_s_8Ddwfp9OJnpyefTuAB35T1ilk8RD218tNcYQ0ap29bmrNNeUeDls
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwED6xIU28IH6TbYBBvIHVJI6d5HHaGjbYpj60aG-WE8dQbXOmrn3gv-cuSVsKA4lIUaLkYjm5s--LffcZ4H2SopvITcZlGSmeJM7y0uUWWzx6dxuHVipKcD47V8eT5POFvPgli7-Ndl9OSXY5DcTS5OeDG-sG68Q3gcgFf4NxDxXF0G7B_YQuokVP4oPVKEso4jxsiTNp6SUukjTpM2fuLmbDO235mbsLeP4ZP_nbJGrrm4pH8LAHleygs4LHcK_2T2DnrJ82fwrlaEbn1LOxr-ZqUbPGsXYscHrNjLds6C1vHB93FAMsygpeHH1io-F4cDhmU89GHf3qLaNxW1YQk3cbwMpOf6A5NNfmGUyK4fjwmPeLK_AKMdmcW6OyJDLYvdhMKUs6EQ43W1aREWEV10qhFh0CBFkqK12aWmGqCvEVYT4jnsO2b3z9EliOZUmj0pzI7xKZmlzIMleVs5mUWGAA0fKj6qpnHqcFMK70mjOZFKFREbpVhA4D-LB65qbj3fin9DvUlb6spprosun4rdGXM40_BSda5oRqUWh_qUrdN9RbHSN8E3GGuC-At6vb2MRo3sT4ulmQDKIadChhFMCLTvOrOokIEWgm8wDSDZtYCVB9Nu_46feWxlsp4uaLA_i4tJ51tf7-qrv_J_4GdkZHhT49Of-yBw_i1tQpenEftuezRf0KEdW8fN02mp9vAhKX
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+Value+of+Interim+and+End-of-Therapy+18F-FDG+PET%2FCT+in+Patients+with+Follicular+Lymphoma&rft.jtitle=Nuclear+medicine+and+molecular+imaging&rft.au=Boo%2C+Sun+Ha&rft.au=O%2C+Joo+Hyun&rft.au=Kwon%2C+Soo+Jin&rft.au=Yoo%2C+Ie+Ryung&rft.date=2019-08-01&rft.issn=1869-3474&rft.volume=53&rft.issue=4&rft.spage=263&rft_id=info:doi/10.1007%2Fs13139-019-00602-0&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1869-3474&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1869-3474&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1869-3474&client=summon